File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Role of hepatic trisectionectomy in advanced hepatocellular carcinoma

TitleRole of hepatic trisectionectomy in advanced hepatocellular carcinoma
Authors
KeywordsCirrhosis
Hepatocellular carcinoma
Trisectionectomy
Issue Date2017
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/suronc
Citation
Surgical Oncology, 2017, v. 26 n. 3, p. 310-317 How to Cite?
AbstractBackground Advanced hepatocellular carcinoma (HCC) with underlying cirrhosis poses a major operative challenge. Patients have a dismal prognosis without curative resection. The role of hepatic trisectionectomy in these patients is not established. The aim of this study was to analyze and compare the perioperative outcome and prognosis of patients undergoing trisectionectomy with hepatic resection of a lesser extent. Methods From 2000 to 2014, 48 patients underwent hepatic trisectionectomy for HCC with background cirrhosis or chronic hepatitis (Group A). Another (Group B) 520 patients underwent liver resection of a lesser extent. Patient demographics, clinicopathological data, perioperative outcome and long-term survival were compared between the 2 groups. Results Intraoperative bloodloss, operating time and total hospital stay were significantly higher in trisectionectomy patients. Tumors were larger and more advanced in group A. The morbidity rate was 43.8% in group A compared to 27.5% in group B, p = 0.027. In-hospital mortality was 6.3% for group A. Group A had a significantly shorter time to recurrence (4.5months vs 6.2months, p = 0.036), as well as a poorer disease-free survival (DFS) than group B (6.3 months vs 15.7 months, p = 0.02). Overall survival was comparable. Tumor number, size, albumin, INR, microvascular invasions and positive resection margins were predictors of disease-free survival. Conclusion Hepatic trisectionectomy may be associated with a higher morbidity and lower DFS. However, these patients would not be suitable candidates for ablative therapy or liver transplantation. With careful patient selection and meticulous surgical technique, trisectionectomy is feasible and gives these patients the only hope of cure.
Persistent Identifierhttp://hdl.handle.net/10722/259539
ISSN
2021 Impact Factor: 2.388
2020 SCImago Journal Rankings: 0.989
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTsang, JS-
dc.contributor.authorChok, KSH-
dc.contributor.authorLo, CM-
dc.date.accessioned2018-09-03T04:09:35Z-
dc.date.available2018-09-03T04:09:35Z-
dc.date.issued2017-
dc.identifier.citationSurgical Oncology, 2017, v. 26 n. 3, p. 310-317-
dc.identifier.issn0960-7404-
dc.identifier.urihttp://hdl.handle.net/10722/259539-
dc.description.abstractBackground Advanced hepatocellular carcinoma (HCC) with underlying cirrhosis poses a major operative challenge. Patients have a dismal prognosis without curative resection. The role of hepatic trisectionectomy in these patients is not established. The aim of this study was to analyze and compare the perioperative outcome and prognosis of patients undergoing trisectionectomy with hepatic resection of a lesser extent. Methods From 2000 to 2014, 48 patients underwent hepatic trisectionectomy for HCC with background cirrhosis or chronic hepatitis (Group A). Another (Group B) 520 patients underwent liver resection of a lesser extent. Patient demographics, clinicopathological data, perioperative outcome and long-term survival were compared between the 2 groups. Results Intraoperative bloodloss, operating time and total hospital stay were significantly higher in trisectionectomy patients. Tumors were larger and more advanced in group A. The morbidity rate was 43.8% in group A compared to 27.5% in group B, p = 0.027. In-hospital mortality was 6.3% for group A. Group A had a significantly shorter time to recurrence (4.5months vs 6.2months, p = 0.036), as well as a poorer disease-free survival (DFS) than group B (6.3 months vs 15.7 months, p = 0.02). Overall survival was comparable. Tumor number, size, albumin, INR, microvascular invasions and positive resection margins were predictors of disease-free survival. Conclusion Hepatic trisectionectomy may be associated with a higher morbidity and lower DFS. However, these patients would not be suitable candidates for ablative therapy or liver transplantation. With careful patient selection and meticulous surgical technique, trisectionectomy is feasible and gives these patients the only hope of cure.-
dc.languageeng-
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/suronc-
dc.relation.ispartofSurgical Oncology-
dc.subjectCirrhosis-
dc.subjectHepatocellular carcinoma-
dc.subjectTrisectionectomy-
dc.titleRole of hepatic trisectionectomy in advanced hepatocellular carcinoma-
dc.typeArticle-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityChok, KSH=rp02110-
dc.identifier.authorityLo, CM=rp00412-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.suronc.2017.07.001-
dc.identifier.pmid28807252-
dc.identifier.scopuseid_2-s2.0-85021724067-
dc.identifier.hkuros288610-
dc.identifier.volume26-
dc.identifier.issue3-
dc.identifier.spage310-
dc.identifier.epage317-
dc.identifier.isiWOS:000410652800014-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0960-7404-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats